Obesity, adipokines, and prostate cancer (review)

Jacques Baillargeon, David P. Rose

Research output: Contribution to journalArticle

93 Citations (Scopus)

Abstract

Prostate cancer, the third most common cancer in men worldwide, varies substantially according to geographic region and race/ethnicity. Obesity and associated endocrine variation are foremost among the risk factors that may underlie these regional and ethnic differences. The association between obesity and prostate cancer incidence is complex and has yielded inconsistent results. Studies that have linked obesity with prostate cancer mortality, advanced stage disease, and higher grade Gleason score, however, have produced more consistent findings, indicating that obesity may not necessarily increase the risk of prostate cancer, but may promote it once established. Additionally, metabolic syndrome, which includes disturbed glucose metabolism and insulin bioactivity, may also be associated with prostate carcinogenesis. Adipokines, defined as biologically active polypeptides produced by adipose tissue, have been linked with a number of carcinogenic mechanisms, including angiogenesis, cell proliferation, metastasis, and alterations in sex-steroid hormone levels. A number of emerging studies have implicated the role of adipokines in prostate carcinogenesis. This review explores the specific roles of several adipokines as putative mediating factors between obesity and prostate cancer with particular attention to leptin, interleukin-6 (IL-6), heparin-binding epidermal growth factor-like growth factor (HB-EGF), vascular endothelial growth factor (VEGF) and adiponectin.

Original languageEnglish (US)
Pages (from-to)737-745
Number of pages9
JournalInternational Journal of Oncology
Volume28
Issue number3
StatePublished - Mar 2006
Externally publishedYes

Fingerprint

Adipokines
Prostatic Neoplasms
Obesity
Prostate
Carcinogenesis
Neoplasm Grading
Adiponectin
Gonadal Steroid Hormones
Leptin
Epidermal Growth Factor
Vascular Endothelial Growth Factor A
Heparin
Adipose Tissue
Interleukin-6
Intercellular Signaling Peptides and Proteins
Cell Proliferation
Insulin
Neoplasm Metastasis
Glucose
Peptides

Keywords

  • Adipokines
  • Adiponectin
  • Body mass index
  • Cytokines
  • Leptin
  • Obesity
  • Prostate cancer

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Obesity, adipokines, and prostate cancer (review). / Baillargeon, Jacques; Rose, David P.

In: International Journal of Oncology, Vol. 28, No. 3, 03.2006, p. 737-745.

Research output: Contribution to journalArticle

@article{6c0e437209c2416483695680a64f4072,
title = "Obesity, adipokines, and prostate cancer (review)",
abstract = "Prostate cancer, the third most common cancer in men worldwide, varies substantially according to geographic region and race/ethnicity. Obesity and associated endocrine variation are foremost among the risk factors that may underlie these regional and ethnic differences. The association between obesity and prostate cancer incidence is complex and has yielded inconsistent results. Studies that have linked obesity with prostate cancer mortality, advanced stage disease, and higher grade Gleason score, however, have produced more consistent findings, indicating that obesity may not necessarily increase the risk of prostate cancer, but may promote it once established. Additionally, metabolic syndrome, which includes disturbed glucose metabolism and insulin bioactivity, may also be associated with prostate carcinogenesis. Adipokines, defined as biologically active polypeptides produced by adipose tissue, have been linked with a number of carcinogenic mechanisms, including angiogenesis, cell proliferation, metastasis, and alterations in sex-steroid hormone levels. A number of emerging studies have implicated the role of adipokines in prostate carcinogenesis. This review explores the specific roles of several adipokines as putative mediating factors between obesity and prostate cancer with particular attention to leptin, interleukin-6 (IL-6), heparin-binding epidermal growth factor-like growth factor (HB-EGF), vascular endothelial growth factor (VEGF) and adiponectin.",
keywords = "Adipokines, Adiponectin, Body mass index, Cytokines, Leptin, Obesity, Prostate cancer",
author = "Jacques Baillargeon and Rose, {David P.}",
year = "2006",
month = "3",
language = "English (US)",
volume = "28",
pages = "737--745",
journal = "International Journal of Oncology",
issn = "1019-6439",
publisher = "Spandidos Publications",
number = "3",

}

TY - JOUR

T1 - Obesity, adipokines, and prostate cancer (review)

AU - Baillargeon, Jacques

AU - Rose, David P.

PY - 2006/3

Y1 - 2006/3

N2 - Prostate cancer, the third most common cancer in men worldwide, varies substantially according to geographic region and race/ethnicity. Obesity and associated endocrine variation are foremost among the risk factors that may underlie these regional and ethnic differences. The association between obesity and prostate cancer incidence is complex and has yielded inconsistent results. Studies that have linked obesity with prostate cancer mortality, advanced stage disease, and higher grade Gleason score, however, have produced more consistent findings, indicating that obesity may not necessarily increase the risk of prostate cancer, but may promote it once established. Additionally, metabolic syndrome, which includes disturbed glucose metabolism and insulin bioactivity, may also be associated with prostate carcinogenesis. Adipokines, defined as biologically active polypeptides produced by adipose tissue, have been linked with a number of carcinogenic mechanisms, including angiogenesis, cell proliferation, metastasis, and alterations in sex-steroid hormone levels. A number of emerging studies have implicated the role of adipokines in prostate carcinogenesis. This review explores the specific roles of several adipokines as putative mediating factors between obesity and prostate cancer with particular attention to leptin, interleukin-6 (IL-6), heparin-binding epidermal growth factor-like growth factor (HB-EGF), vascular endothelial growth factor (VEGF) and adiponectin.

AB - Prostate cancer, the third most common cancer in men worldwide, varies substantially according to geographic region and race/ethnicity. Obesity and associated endocrine variation are foremost among the risk factors that may underlie these regional and ethnic differences. The association between obesity and prostate cancer incidence is complex and has yielded inconsistent results. Studies that have linked obesity with prostate cancer mortality, advanced stage disease, and higher grade Gleason score, however, have produced more consistent findings, indicating that obesity may not necessarily increase the risk of prostate cancer, but may promote it once established. Additionally, metabolic syndrome, which includes disturbed glucose metabolism and insulin bioactivity, may also be associated with prostate carcinogenesis. Adipokines, defined as biologically active polypeptides produced by adipose tissue, have been linked with a number of carcinogenic mechanisms, including angiogenesis, cell proliferation, metastasis, and alterations in sex-steroid hormone levels. A number of emerging studies have implicated the role of adipokines in prostate carcinogenesis. This review explores the specific roles of several adipokines as putative mediating factors between obesity and prostate cancer with particular attention to leptin, interleukin-6 (IL-6), heparin-binding epidermal growth factor-like growth factor (HB-EGF), vascular endothelial growth factor (VEGF) and adiponectin.

KW - Adipokines

KW - Adiponectin

KW - Body mass index

KW - Cytokines

KW - Leptin

KW - Obesity

KW - Prostate cancer

UR - http://www.scopus.com/inward/record.url?scp=33645234011&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33645234011&partnerID=8YFLogxK

M3 - Article

C2 - 16465380

AN - SCOPUS:33645234011

VL - 28

SP - 737

EP - 745

JO - International Journal of Oncology

JF - International Journal of Oncology

SN - 1019-6439

IS - 3

ER -